Announcements LOREM IPSUM

Privacy Policy

This Privacy Policy discloses our privacy practices and how we may use the information that we gather on our website (the “Website”) or that you provide to SalioGen Therapeutics, Inc. or its affiliates (“SalioGen”) through other means. By using the Website or voluntarily providing personal information to us, you consent to the terms of this Privacy Policy. SalioGen may update this Privacy Policy from time to time per our sole discretion and will post the current version on the Website. It is your responsibility to review the Privacy Policy for any changes when you use the Website.

Categories of Information Collected

Information you provide to us. We may collect personal information from you in a variety of ways in connection with activities, services, features or resources we make available on our Website. This information may include, without limitation, your name, address, email address, phone number, cell phone number, and demographic information. Additionally, if you participate in certain SalioGen programs we may collect certain health-related information about you, including without limitation, your medications, your health history, and other information which may be deemed “Protected Health Information” as defined in the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations, and in particular at 45 C.F.R. § 160.103, as it may be amended from time to time.

Information we collect automatically. In certain circumstances, we may collect information from you automatically, such as your IP address or information about the ways you browse and interact with our Website. For more information, see our Cookie Policy, below.

Purposes of Collection

SalioGen may collect and use the categories of personal information described above for the following purposes:

  • To improve the Website;
  • To notify you about updates to the Website;
  • Internal business analysis or other business purposes consistent with our mission;
  • To prevent potentially prohibited or illegal activities or to enforce this Privacy Policy or our Terms of Use;
  • To carry out other purposes that are disclosed to you and to which you consent;
  • To comply with applicable laws, court orders, or legal processes; and
  • To contact you or communicate with you.


We may use non-personal information for any purpose.

Third Parties with Whom We Share the Categories of Personal Information Collected

We do not sell, trade, or rent your personal information to others. However, we may share any information we receive with vendors, service providers, and business partners that we use to help us provide and improve our services. We may aggregate and anonymize data collected through our services and Website and use and share such information with our business partners, services providers, affiliates and advertisers for the purposes outlined above.

In the event that a division, assets or part or all of SalioGen is bought, sold or otherwise transferred, or is in the process of a potential transaction, your information will likely be shared for evaluation purposes and be included among the transferred business assets.

SalioGen may also disclose specific information when such disclosure appears necessary to comply with the law, a subpoena or other litigation process or to protect the interests or safety of its visitors and customers, employees or others. This includes exchanging information with other companies and organizations for fraud protection and credit risk reduction.

How we protect your information

We adopt what we believe to be reasonable data collection, storage and processing practices and security measures to protect against unauthorized access, alteration, disclosure or destruction of your personal information and data stored on our Website. However, no commercial method of information transfer over the internet or electronic data storage is known to be 100% secure. As a result, we cannot guarantee the absolute security of that information during its transmission or its storage in our systems.

Do Not Track

Do Not Track (DNT) is a privacy preference that users can set in some web browsers, allowing users to opt out of tracking by Websites and online services. At the present time, the World Wide Web Consortium (W3C) has not yet established universal standards for recognizable DNT signals and therefore, SalioGen and the Website do not recognize DNT.

Third-Party Sites

This Privacy Policy does not cover, supersede or affect the terms of any policy or agreement between you and any third party (such as third-party credit card processors, Facebook, LinkedIn, our partners, advertisers, vendors or other third parties who appear on the Website or who link to or from the Website and other parties with whom you share personal information) (“Third-Party Sites”). If you choose to do business with or provide personal information to such Third-Party Sites, you do so entirely at your own risk and we have no responsibility or liability for the content and activities of these Third-Party Sites. Nonetheless, we seek to protect the integrity of the Website and welcome any feedback about these Third-Party Sites (including if a specific link does not work).

Changes to This Privacy Policy

SalioGen has the discretion to update this privacy policy at any time, and we will post the current version on the Website. Your continued relationship with us after the posting or notice of any amended Privacy Policy will constitute your agreement to be bound by any such changes. Any changes to this Privacy Policy take effect immediately after being posted or otherwise provided by us.

Children’s Privacy

SalioGen is concerned about the privacy and safety of children when they use the Internet. We do not knowingly collect any personal information from children under the age of 13 without verifiable parental consent. Our products and services are for adults only and our Website is not directed at children.

Your California Privacy Rights

Under the law of certain states, including California Civil Code § 1798.83, you are entitled once per calendar year to obtain information from us about who your personal information has been shared with for their own direct marketing purposes. In order to obtain this information, if applicable, or for other questions or comments regarding our privacy policies, you may contact us as described below.

If you are a California resident, California law provides you with the following additional rights with respect to your personal information, subject to certain limitations:

  • The right to know what personal information we have collected, used, disclosed and sold about you. To submit a request to know, you may call or contact us by any of the means indicated on the SalioGen Contact Us webpage. You also may designate an authorized agent to make a request for access on your behalf by contacting us by any of the means indicated on the SalioGen Contact Us webpage.
  • The right to request that we delete any personal information we have collected about you. To submit a request for deletion, you may call or contact us by any of the means indicated on the SalioGen Contact Us webpage. You also may designate an authorized agent to make a request for deletion on your behalf by contacting us by any of the means indicated on the SalioGen Contact Us webpage.


When you exercise these rights and submit a request to us, we will verify your identity by asking you for your email address, telephone number, or other information about you. We also may use a third-party verification provider to verify your identity.

For the 12-month period prior to the date of this Privacy Policy, SalioGen has not sold any personal information about California residents; nor does it have any plans to do so in the future.

Transferring Information to Other Countries

It is important to note that the Website is offered under United States law. If you are not in the United States, you understand and agree that we may transfer to and store your personal information in the United States, which—depending on where you are located—may not be viewed as having the same data protections as the country where you reside. We may also transfer your information to other countries, which may have different data protections laws from the United States. By using the Website and/or providing us with your information, you consent to such transfers.

Contacting Us

If you have any questions about this Privacy Policy, and SalioGen’s policies and practices with respect to personal information, please contact us by any of the means indicated on the SalioGen Contact Us webpage.

Jason F. Cole

CEO & Chairman of the Board

Jason is a strategic biotechnology CEO and board member with over 20 years of experience working with public and private biotech companies focused on strategy, capital raising, business development, operations, and enabling teams.

Jason joined SalioGen from bluebird bio, where he served as Chief Strategy and Financial Officer, Chief Business Officer, and Chief Operating and Legal Officer, providing strategic, financial, operational, and legal oversight during key growth and transition periods. In these roles, bluebird bio scaled from 100 to 1,200 employees (U.S. & Europe), secured FDA approval of three first-of-their-kind gene and cell therapies (ZYNTEGLO, SKYSONA, ABECMA), and closed over $3.7 billion in financings and strategy-enabling business development transactions. Before bluebird bio, Jason held positions on the executive leadership teams of Zalicus and CombinatoRx, with responsibility across corporate development, strategic alliances, legal, IT, and facilities.

Jason earned a J.D. from Columbia University and an A.B. in Government from Dartmouth College.

Joseph J. Higgins, M.D.

Chief Innovation Officer, Co-Founder & Board Member

Joe is an executive leader, clinician, and scientist dedicated to advancing gene therapies for children and adults with genetic disorders involving the cardiovascular, ophthalmological, neurological, and immunological systems. His background spans pediatrics, child neurology, medical genetics, and molecular developmental neurobiology.

Earlier in his career, Joe worked on the Human Genome Project as the lead of the Human Genetic Initiative. His academic background includes positions as an instructor at Harvard Medical School, an Assistant Professor at George Washington University, an Associate Professor at SUNY Albany, and a Professor at Cornell University. As the Vice President of Clinical Development at uniQure, Joe led Phase 1/2 first-in-human gene therapy trials in Huntington’s disease.

Joe received his medical degree from New York University and graduated cum laude with a B.A. in Biology from Marist College. He is double-board certified in Pediatrics and Neurology with Special Qualification in Child Neurology. He is licensed to practice medicine in New York and Massachusetts.

Jeff Kopacz, M.S., J.D.

Senior Vice President, Intellectual Property & Contracts

Jeff has extensive intellectual property (IP) experience, including building and defending IP protection for platform-based technologies and FDA-approved therapeutics.

Previously, Jeff served as Vice President of Intellectual Property at Omega Therapeutics, leading IP and contract activities related to their genomic control technology. Before Omega, Jeff worked at Alnylam Pharmaceuticals for ten years, most recently as Senior Director, Senior Intellectual Property counsel.

Earlier, Jeff was an attorney at Edwards Angell Palmer & Dodge LLP (now Locke Lord LLP) Jeff began his biopharma career at Millennium Pharmaceuticals (now Takeda Pharmaceuticals).

Jeff received his undergraduate degree in microbiology from the University of Massachusetts at Amherst, his graduate degree in molecular microbiology and immunology from Johns Hopkins University, and a law degree from Suffolk University Law School.

Kate Lewis

Vice President, Portfolio and Program Management

Kate is a biotech leader with 20 years of experience in life sciences and drug development, including extensive work in gene therapy. Her focus is portfolio management, strategic planning, communications, and team leadership.

Prior to SalioGen, Kate served as Vice President, Program Lead and Head of Program Management at Syndax Pharmaceuticals and Freeline Therapeutics. Before that, Kate spent nearly seven years at bluebird bio in roles in Medical Affairs and Program Leadership.

Kate holds a B.A. from Pomona College and an M.A. from the University of Iowa, both in English literature.

Will McGowan

Executive Director, Finance & FP&A

Will is a financial leader with over 15 years of experience working in both public and private biotech companies at all stages of development, from discovery through commercialization.

Will most recently was the Senior Director of FP&A for Allena Pharmaceuticals. Before that role, He spent five years as the Senior Director of Finance and Controller for Navitor Pharmaceuticals and nine years at AMAG Pharmaceuticals in various roles, including Controller and Director of FP&A.

Will holds an MBA from Quinnipiac University and a Bachelor of Science in Finance and Accounting from the Darla Moore School of Business at the University of South Carolina.

Jill Murray

Vice President, Human Resources

Jill is a senior human resources professional with 20+ years of progressive experience in the biotech industry. Her focus is organizational design, employee development, employee relations, leadership coaching, change management, compensation, benefits administration, and legal compliance.

Jill began her career at ImmunoGen, where she covered all facets of Human Resources and Talent Management during her 14-year tenure. After that, Jill joined Sarepta Therapeutics, where she was responsible for establishing and building the HR Business Partnering function, followed by Rubius Therapeutics where she served as Head of Human Resources.

Jill holds a bachelor’s degree in art and psychology from Carnegie Mellon University and is a certified Executive Coach.

Sandeep Nema, Ph.D.

Senior Vice President, Technical Operations

Sandeep has extensive developmental experience in bringing candidates to clinic that span various modalities, including gene therapy, ADCs, mAbs, vaccines, oligonucleotides, bi/tri-specific, and CART.

Before SalioGen, Sandeep worked for 24 years at Pfizer. Recently, his team successfully brought Pfizer’s COVID-19 LNP-mRNA vaccine to the clinic and achieved emergency use authorization. In his last role as Executive Director, Biotherapeutics Pharmaceutical Sciences, Global Biologics, Sandeep was responsible for all pre-proof-of-concept biologics projects, approximately 50 in total, from discovery up to Phase 3 start. Before that, Sandeep established the Protein Pharmaceutical R&D group at Pfizer, which included Formulation, Microbiology, and Stability functions. He is also an adjunct Professor at the University of Tennessee.

Sandeep earned his Ph.D. in Pharmaceuticals from the University of Tennessee Health Science Center and his Bachelor of Pharmacy from Banaras Hindu University. He is also a Certified Regulatory Affairs Professional.

Joe Senn, Ph.D.

Senior Vice President, Head of R&D

Joe is an R&D leader with experience in nearly all therapeutic modalities, including small molecules, biologics, antisense, gene editing, and mRNA therapeutics. He most recently served as the Vice President of Nonclinical Development at Moderna Therapeutics, where he and his team were responsible for progressing over 40 candidates into the clinic. Before Moderna, Joe served as Site Head for Drug Safety at Takeda Pharmaceuticals, overseeing the development of all immunology products across the portfolio.

Joe earned his Ph.D. in Pharmacology and Physiology from the University of Rochester School of Medicine and Dentistry and his B.S. from Niagara University.